±Ñ¸ì Ãæ¹ñ´ÊÂÎ Ãæ¹ñÈËÂÎ ´Ú¹ñ¸ì

¥¸¥å¥Ó¥À¡¼¥à¥Ó¥¹¥¿®
¥Ü¥ê¥Õ¥È XC

ºÇ½ª¹¹¿·Æü:  2024ǯ03·î21Æü

  • µ­»ö¡§´Æ½¤°å»Õ
    ÆüËÜÈþÍƳ°²Ê°å»Õ²ñÍý»ö
    ÆüËÜÈþÍƳ°²Ê³Ø²ñǧÄêÀìÌç°å
    µ×¼¡ÊÆ¡¡½©¿Í

  • ´Æ½¤¤Îµ×¼¡ÊÆÍý»öĹ
¥¸¥å¥Ó¥À¡¼¥à¥Ó¥¹¥¿ ¥Ü¥ê¥Õ¥È XC

¥Ü¥ê¥Õ¥È XC¤È¤Ï

¥Ü¥ê¥Õ¥È XC¤Î¥Ñ¥Ã¥±¡¼¥¸³°´Ñ

¥Ü¥ê¥Õ¥È XC¤Ï¡¢¥¢¥é¥¬¥ó¡¦¥¸¥ã¥Ñ¥ó¼Ò¤¬À½Â¤ÈÎÇ䤹¤ë¥¸¥å¥Ó¥À¡¼¥à¥Ó¥¹¥¿®¥·¥ê¡¼¥º¤Î¥Ò¥¢¥ë¥í¥ó»À¤Î1¼ï¤Ç¤¹¡£¼ç¤Ë¡¢①¥·¥ï¤Î²þÁ±¡¢②´é¤Î¹Â¡¢③È©¤Î¼Á´¶¤Î²þÁ±¤Ë»ÈÍѤµ¤ì¤Þ¤¹¡£

¥Ü¥ê¥å¡¼¥Þ¤¬XC¤è¤ê¾¯¤·½À¤é¤«¤¤¥Ò¥¢¥ë¥í¥ó»À¤Ë¤Ê¤ê¤Þ¤¹¡£
¤½¤Î¤¿¤á¡¢¹Å¤¤¥Ü¥ê¥å¡¼¥ÞXC¤È°ì½ï¤Ë»ÈÍѤµ¤ì¤ë¤³¤È¤¬Â¿¤¤¤Ç¤¹¡£

¥Ü¥ê¥Õ¥È XC¤ÏÆüËܤˤª¤¤¤Æ¡¢¡Ö¥·¥ï¤È¤ß¤¾¼£ÎšפȤ·¤Æ¸üÀ¸Ï«Æ¯¾Ê¤«¤é¾µÇ§¤òÆÀ¤Æ¤¤¤Þ¤¹¡£

¥Ü¥ê¥Õ¥È XC¤ò»ý¤Ä°å»Õ¤È´µ¼ÔÍÍ

ÈþÍÆ°åÎŤǻÈÍѤ¹¤ë¥Ò¥¢¥ë¥í¥ó»À¤Ï¼ïÎब¿¤¯¡¢À¤³¦³Æ¹ñ¤ÇÈó¾ï¤Ë¿¤¯¤Î¥Ò¥¢¥ë¥í¥ó»À¤¬È¯Ç䤵¤ì¤Æ¤¤¤Þ¤¹¡£¤É¤Î¥Ò¥¢¥ë¥í¥ó»À¤ò¤É¤Î¼£ÎŤ˻ÈÍѤ¹¤ë¤Î¤«¡¢°ìÈ̤ÎÊý¤Ç¤Ï¤Ê¤«¤Ê¤«Ê¬¤«¤ê¤Å¤é¤¤¤È»×¤¤¤Þ¤¹¡£

¥Ò¥¢¥ë¥í¥ó»À¤ÎÍÑÅӤϼ¤Ë¿Íͤǡ¢¥·¥ï¼£ÎŤ䶻¤òËĤé¤Þ¤¹¼ê½Ñ¡¢É¡¤ä³Ü¤ò·ÁÀ®¤¹¤ë¼ê½Ñ¤Ê¤ÉÍÍ¡¹¤ÊÍÑÅÓ¤ÇÈþÍÆ°åÎŤǻÈÍѤµ¤ì¤Æ¤¤¤Þ¤¹¡£

¤½¤ÎÃæ¤Ç¥Ü¥ê¥Õ¥ÈXC¤Ï¡¢¥·¥ï¼£ÎŤ䥷¥ï¤¬¿Ê¤ó¤Ç¹Â¡Ê¤ß¤¾¡Ë¤Ë¤Ê¤Ã¤¿²Õ½ê¤Î¼£ÎŤ˻ÈÍѤµ¤ì¤Þ¤¹¡£

¥Ü¥ê¥Õ¥È XC¤ÏÌó12~18¥õ·î»ý³¤·¤Þ¤¹

¥Ò¥¢¥ë¥í¥ó»À¤ÎÎ̤¬Ç»¤¤¤È¸Ç¤¯¤Ê¤ê¤Þ¤¹¤¬¡¢¥Ü¥ê¥Õ¥È XC¤Ï½À¤é¤«¤¤¥Ò¥¢¥ë¥í¥ó»À¤Î¤¿¤á¡¢¥Ò¥¢¥ë¥í¥ó»À¤ÎÇ»ÅÙ¤¬Ä㤤¤Ç¤¹¡£¸Ä¿Íº¹¤Ï¤¢¤ê¤Þ¤¹¤¬¡¢¥Ü¥ê¥Õ¥È XC¤ÏÇ»ÅÙ¤¬Ä㤤¤Ë¤â´Ø¤ï¤é¤º¡¢Ìó12~Ìó18¥ö·î»ý³¤·¤Þ¤¹¡£

  • »²¹Í¡§Allergan DOF - VOLIFT 003 Clinical Study, Allergan DOF - VOLIFT-006-JAN 2015 15 month duration, Eccleston D, Murphy DK. Clin Cosmet Investig Dermatol. 2012; 5:167-172

´é¤ÎÀõ¤¤¥·¥ï¤ä¹Â¤Î¥Ü¥ê¥å¡¼¥à¥¢¥Ã¥×¤Ë»ÈÍѤµ¤ì¤ëÄãÇ»Å٤Υҥ¢¥ë¥í¥ó»À¤Ç¤¹¡£

¥Ü¥ê¥Õ¥È XC¤ÎŬ±þ²Õ½ê

¥Ü¥ê¥Õ¥È XC¤ÎŬ±þ²Õ½ê
  • ¤Û¤¦¤ì¤¤Àþ
  • ¤ª¤Ç¤³
  • Èý´Ö
  • ÌÜ¿¬
  • Ìܤβ¼
  • ¥´¥ë¥´¥é¥¤¥ó
  • ¸ý¤Î¼þ¤ê
  • ¥Þ¥ê¥ª¥Í¥Ã¥È¥é¥¤¥ó

¤³¤Î¤è¤¦¤ÊÊý¤Ë¸þ¤¤¤Æ¤¤¤Þ¤¹

¥Ü¥ê¥Õ¥È XC¤Ï¤³¤Î¤è¤¦¤ÊÊý¤Ë¸þ¤¤¤Æ¤¤¤Þ¤¹
  • ¤Û¤¦¤ì¤¤Àþ¤¬ÌÜΩ¤ÄÊý
  • ¥·¥ï¤¬µ¤¤Ë¤Ê¤ëÊý
  • ´é¤Î¹Â¤¬µ¤¤Ë¤Ê¤ëÊý
  • Ìܤβ¼¤Î¥Ü¥ê¥å¡¼¥à¸º¾¯(±ú¤ß)¤¬µ¤¤Ë¤Ê¤ëÊý
  • ÌÀ¤ë¤¤°õ¾Ý¤Îɽ¾ð¤Ë¤µ¤ì¤¿¤¤Êý
  • ¾®â²¤¬ÌÜΩ¤ÄÊý
  • »ý³À­¤¬µ¤¤Ë¤Ê¤ëÊý
  • ¥á¥¹¤ò»È¤ï¤Ê¤¤»Ü½Ñ¤ò¤´´õ˾¤ÎÊý
  • ½Ñ¸å¤Î¥À¥¦¥ó¥¿¥¤¥à¤òµ¤¤Ë¤¹¤ëÊý
  • Äˤߤ¬¶ì¼ê¤ÊÊý

¥·¥ï¤ä¹Â¤ò²¼¤«¤é»ý¤Á¾å¤²¤ë¥Ò¥¢¥ë¥í¥ó»À

¥·¥ï¤ä¹Â¤ò²¼¤«¤é»ý¤Á¾å¤²¤ë¥Ò¥¢¥ë¥í¥ó»À XC

¥Ü¥ê¥Õ¥È XC¤Ï¡¢Àõ¤¤ÁؤËÃíÆþ¤¹¤ë¤³¤È¤¬¤Ç¤­¤ë¤è¤¦¡¢½À¤é¤«¤¯ºî¤é¤ì¤Æ¤¤¤Þ¤¹¡£¹Å¤¤¥Ò¥¢¥ë¥í¥ó»À¤Î¾ì¹ç¡¢ÈéÉæ¤ÎɽÌ̤˶ᤤÀõ¤¤ÁؤËÆþ¤ì¤Æ¤·¤Þ¤¦¤ÈɽÌ̤¬¥Ç¥³¥Ü¥³¤·¤Æ¤·¤Þ¤¤¤Þ¤¹¡£

¤½¤Î¤¿¤á¥Ü¥ê¥Õ¥È XC¤Ï¡¢½À¤é¤«¤¯ºî¤é¤ì¤Æ¤ª¤ê¡¢Àõ¤¤ÁؤËÆþ¤ì¤ë¤³¤È¤¬¤Ç¤­¤Þ¤¹¡£¥·¥ï¤ä¹Â¤Î²¼¤Ë¥Ü¥ê¥Õ¥È XC¤òÃíÆþ¤·¡¢¥·¥ï¤ä¹Â¤ò²¼¤«¤é¾å¤Ë»ý¤Á¾å¤²¤Þ¤¹¡£

È©¤Î¼Á´¶²þÁ±¡¢¤Ä¤ä½Ð¤·¤Ë¤â¡£

¥¸¥å¥Ó¥À¡¼¥à¥Ó¥¹¥¿ ¥Ü¥ê¥Õ¥È XC

¥Ü¥ê¥Õ¥È XC¤ÏÈéÉæɽÌ̤ÎÀõ¤¤ÁؤËÃíÆþ¤¹¤ë¤¿¤á¡¢¥Ü¥ê¥Õ¥È XC¤òÃíÆþ¤¹¤ë¤ÈÈéÉæ¤ÎɽÌÌÉÕ¶á¤Ë¥Ò¥¢¥ë¥í¥ó»À¤ÎÎ̤¬Â¿¤¯¤Ê¤ê¤Þ¤¹¡£

¥Ò¥¢¥ë¥í¥ó»À¤Ï¤â¤È¤â¤ÈÂΤˤ¢¤ëÀ®Ê¬¤Î¤¿¤á¡¢¸Ä¿Íº¹¤Ï¤¢¤ê¤Þ¤¹¤¬¡¢ÈéÉæɽÌÌÉÕ¶á¤Î¥Ò¥¢¥ë¥í¥ó»À¤ÎÎ̤¬Â¿¤¯¤Ê¤ë¤È¡¢¥Ü¥ê¥Õ¥È XC¤Î¹â¤¤¿ÆÏÂÀ­¤âÁê¤Þ¤Ã¤Æ¥Ò¥¢¥ë¥í¥ó»À(¥Ü¥ê¥Õ¥È XC)¤¬ÁÈ¿¥¤È¤Ê¤¸¤ß¡¢ÈéÉ椬½á¤¤¡¢È©¤Ë¤Ä¤ä¤¬À¸¤Þ¤ì¤Þ¤¹¡£

  • »²¹Í¡§Hee CK et al. Dermtol Surg 2015; 41(Suppl 1): S373-S381, Muhn C et al. Clin Cosmet Investig Dermatol 2012; 5: 147-158

·ì´É¤ä¿À·Ð¤ò½ý¤Ä¤±¤Ê¤¤¤è¤¦¤ËÃíÆþ

·ì´É¤ä¿À·Ð¤ò½ý¤Ä¤±¤Ê¤¤¤è¤¦¤ËÃíÆþ

¥Ò¥¢¥ë¥í¥ó»ÀÃíÆþ¤Ï°åÎŹ԰٤Ǥ¹¡£Ãí°ÕÅÀ¤È¤·¤Æ¡¢´é¤Ë¤Ï¿¤¯¤Î·ì´É¤ä¿À·Ð¤¬Ä̤äƤ¤¤Þ¤¹¤Î¤Ç¥Ü¥ê¥Õ¥ÈXC¤òÃíÆþ¤¹¤ëºÝ¤Ï¡¢ºÙ¿´¤ÎÃí°Õ¤òʧ¤¤¤Þ¤¹¡£

¥Ò¥¢¥ë¥í¥ó»À¤Ç¡¢´é¤Î·ì´É¤ä¿À·Ð¤Ë¥À¥á¡¼¥¸¤òÍ¿¤¨¤Ê¤¤¤è¤¦¤Ë¤·¤Ê¤±¤ì¤Ð¤Ê¤ê¤Þ¤»¤ó¡£

²ò˶³Ø¤Ë´Ø¤·¤Æ

²ò˶³Ø¤Î¥¤¥á¡¼¥¸

Åö±¡¤Ï°å»Õ¤Ë¡¢²ò˶³Ø¤ò³Ø¤Ö¤è¤¦¤ËµÁ̳ÉÕ¤±¤Æ¤¤¤Þ¤¹¡£

¥Ü¥ê¥Õ¥È XC¤ÎÃíÆþÊýË¡¤ò´é¤ÎÉô°ÌÊ̤ˤ´¾Ò²ð

¥Ò¥¢¥ë¥í¥ó»À¤ÎÃí¼Í¤ò¼õ¤±¤Æ¤¤¤ë¤È¤³¤í

¥Ü¥ê¥Õ¥È XC¤Ï¡¢´é¤Î¥·¥ï¤ä¹Â¡¢¤½¤·¤ÆÈ©¤Î¼Á´¶¤Î²þÁ±¤Ë»ÈÍѤ·¤Þ¤¹¡£¤½¤Î¤¿¤á¡¢´ðËÜŪ¤ËÎÞÂޤ俰°Ê³°¤Î´é¤Î¤É¤ÎÉô°Ì¤Ç¤â»ÈÍѤ¹¤ë¤³¤È¤¬¤Ç¤­¤Þ¤¹¡£

¤³¤³¤Ç¤Ï¡¢³ÆÉô°Ì¤ÎÃíÆþ¥Ý¥¤¥ó¥È¤ÎÌܰ¤ò¤´¾Ò²ð¤·¤Þ¤¹¡£

¤¢¤¯¤Þ¤Ç¤â¤³¤³¤Ç¤´¾Ò²ð¤¹¤ëÃíÆþ¥Ý¥¤¥ó¥È¤Ï¡ÖÌܰ¡פΤ¿¤á¡¢´µ¼ÔÍͤΤ´Í×˾¤ä´é¤Î·Á¡¢°å»Õ¤ÎȽÃÇÅù¤Ë¤è¤ê¡¢ÃíÆþ¥Ý¥¤¥ó¥È¤Ï°Û¤Ê¤ë¾ì¹ç¤¬¤¢¤ê¤Þ¤¹¡£°ÂÁ´Ì̤ÈÈþ¤·¤µ¡¢¤½¤·¤ÆÄˤߤËÇÛθ¤·¤ÆÃíÆþ¤·¤Þ¤¹¡£

¢¡¤Û¤¦¤ì¤¤Àþ

¤Û¤¦¤ì¤¤Àþ¤Ø¤ÎÃíÆþÊýË¡

¤Û¤¦¤ì¤¤Àþ¤Î¥·¥ï¤ä¹Â¤ò¼£ÎŤ¹¤ë¾ì¹ç¡¢¤³¤Î¤è¤¦¤Ë¡¢¤Û¤¦¤ì¤¤Àþ¤Î¥·¥ï¤ä¹Â¤Ë±è¤Ã¤ÆÃíÆþ¤·¤Þ¤¹¡£

¥·¥ï¤ä¹Â¤òËä¤á¤ë¤è¤¦¤Ë¡¢¤Û¤¦¤ì¤¤Àþ¤Î²¼¤ÎÀõ¤¤ÁؤËÃíÆþ¤·¤Þ¤¹¡£´é¤ÎÃæ±ûÉÕ¶á¤Ë¤¢¤ëÂ礭¤ÊÀþ¤òÌÜΩ¤¿¤Ê¤¯¤¹¤ë¤³¤È¤¬¤Ç¤­¤ë¤Î¤Ç¡¢¸Ä¿Íº¹¤Ï¤¢¤ê¤Þ¤¹¤¬´é¤Î°õ¾Ý¤òÊѤ¨¤ë¤³¤È¤¬¤Ç¤­¤Þ¤¹¡£

¢¡³Û(¤ª¤Ç¤³)

³Û(¤ª¤Ç¤³)¤Ø¤ÎÃíÆþÊýË¡

¤ª¤Ç¤³¤Î¥·¥ï¤ä¹Â¤ò¼£ÎŤ¹¤ë¾ì¹ç¡¢¤³¤Î¤è¤¦¤Ë¡¢¤ª¤Ç¤³¤Î¥·¥ï¤ä¹Â¤Ë±è¤Ã¤ÆÃíÆþ¤·¤Þ¤¹¡£

¿¤¯¤Î¾ì¹ç¡¢¤ª¤Ç¤³¤ÎÃæ±û¤òÃæ¿´¤Ë¡¢¤ª¤Ç¤³¤Î¥·¥ï¤ò¿­¤Ð¤¹¤è¤¦¤ËÃíÆþ¤·¤Þ¤¹¡£

¢¡Èý´Ö

Èý´Ö¤Ø¤ÎÃíÆþÊýË¡

Èý´Ö¤Î¥·¥ï¤ä¹Â¤ò¼£ÎŤ¹¤ë¾ì¹ç¡¢¤³¤Î¤è¤¦¤Ë¡¢Èý´Ö¤Î¥·¥ï¤ä¹Â¤Ë±è¤Ã¤ÆÃíÆþ¤·¤Þ¤¹¡£

Èý´Ö¤Î¥·¥ï¤ä¹Â¤ò²þÁ±¤¹¤ë¤³¤È¤Ç¡¢¤³¤ï¤Ð¤Ã¤¿´é¤Î°õ¾Ý¤ò²þÁ±¤¹¤ë¤è¤¦¤Ë¼£ÎŤ·¤Þ¤¹¡£

¢¡ÌÜ¿¬

ÌÜ¿¬¤Ø¤ÎÃíÆþÊýË¡

ÌÜ¿¬¤Î¥·¥ï¤ò¼£ÎŤ¹¤ë¾ì¹ç¡¢¤³¤Î¤è¤¦¤Ë¡¢ÌÜ¿¬¤Î¥·¥ï¤ä¹Â¤Ë±è¤Ã¤ÆÃíÆþ¤·¤Þ¤¹¡£ÌÜ¿¬¤Î¥·¥ï¤ò¿­¤Ð¤¹¤è¤¦¤ËÃíÆþ¤·¤Þ¤¹¡£

¢¡Ìܤβ¼

Ìܤβ¼¤Ø¤ÎÃíÆþÊýË¡

Ìܤβ¼¤Î¥Ü¥ê¥å¡¼¥à¤¬¸º¾¯¤·¤Æ¤¤¤ëÉôʬ¤Ë±è¤Ã¤Æ¡¢Ìܤβ¼¤Î¥Ü¥ê¥å¡¼¥à¤ò½Ð¤¹¤è¤¦¤Ë¥Ü¥ê¥Õ¥È XC¤òÃíÆþ¤·¤Þ¤¹¡£

¢¡¥´¥ë¥´¥é¥¤¥ó

¥´¥ë¥´¥é¥¤¥ó¤Ø¤ÎÃíÆþÊýË¡

ÌÜƬÉնᤫ¤éËˤÎÃæ±û¤Ë¸þ¤«¤Ã¤Æ¼Ð¤á²¼¤ËÆþ¤Ã¤Æ¤¤¤ë¥·¥ï¤Î¥é¥¤¥ó¤ò¡Ö¥´¥ë¥´¥é¥¤¥ó¡×¤È¸Æ¤Ó¤Þ¤¹¡£¤³¤Î¥é¥¤¥ó¤Ë±è¤Ã¤ÆÃíÆþ¤¹¤ë¤³¤È¤Ç¡¢¥´¥ë¥´¥é¥¤¥ó¤òÌÜΩ¤¿¤Ê¤¯¤µ¤»¤Þ¤¹¡£

¢¡¸ý¤Î¼þ¤ê

¸ý¤Î¼þ¤ê¤Ø¤ÎÃíÆþÊýË¡

¸ý¤Î¼þ¤ê¤Î½Ä¥·¥ï¤Ë¤Ï¥Ü¥ê¥Õ¥È XC¤¬¸þ¤¤¤Æ¤¤¤Þ¤¹¡£

¸ý¤Î¼þ¤ê¤Î¶ÚÆù¤Î¿ê¤¨¤È¤È¤â¤Ë¥·¥ï¤¬Áý¤¨¤Æ¤¤¤­¤Þ¤¹¤¬¡¢¥Ü¥ê¥Õ¥È XC¤ò¥·¥ï¤ä¹Â¤òËä¤á¤ë¤è¤¦¤ËÃíÆþ¤¹¤ë¤³¤È¤Ç¡¢¥·¥ï¤¬ÌÜΩ¤¿¤Ê¤¤¸ý¸µ¤Ë¤¹¤ë¤³¤È¤¬¤Ç¤­¤Þ¤¹¡£

¢¡¥Þ¥ê¥ª¥Í¥Ã¥È¥é¥¤¥ó

¥Þ¥ê¥ª¥Í¥Ã¥È¥é¥¤¥ó¤Ø¤ÎÃíÆþÊýË¡

¸ý¤Îξ¥µ¥¤¥É¤«¤é¡¢¤¢¤´¤Î²¼¤Ë¤«¤±¤Æ½Ð¤Æ¤·¤Þ¤¦¥·¥ï¤Î¥é¥¤¥ó¤ò¡¢Ê¢ÏýѤοͷÁ(¥Þ¥ê¥ª¥Í¥Ã¥È)¤Î¸ý¸µ¤Ë»÷¤Æ¤¤¤ë¤³¤È¤«¤é¡¢¥Þ¥ê¥ª¥Í¥Ã¥È¥é¥¤¥ó¤È¸Æ¤Ó¤Þ¤¹¡£

¥é¥¤¥ó¤òËä¤á¤ë¤è¤¦¤Ë¥Ü¥ê¥Õ¥È¤òÃíÆþ¤¹¤ë¤³¤È¤Ç¡¢¤³¤Î¥Þ¥ê¥ª¥Í¥Ã¥È¥é¥¤¥ó¤â²þÁ±¤Ç¤­¤Þ¤¹¡£

¤³¤Î¤è¤¦¤ÊÅÀ¤ËÇÛθ¤·¤Æ¥Ü¥ê¥Õ¥È XC¤Î»Ü½Ñ¤ò¹Ô¤Ã¤Æ¤¤¤Þ¤¹

¼«Á³¤Ê»Å¾å¤¬¤ê¤Ë¤Ê¤ë¤è¤¦¤Ë

¼«Á³¤Ê»Å¾å¤¬¤ê¤Ë¤Ê¤ë¤è¤¦¤Ë

´é¤Î°õ¾Ý¤¬ÊѤï¤Ã¤¿¤È´¶¤¸¤ë¤Î¤Ï¡¢²ÃÎð¤Ë¤è¤ê¥Ü¥ê¥å¡¼¥à¤¬¸º¾¯¤·¤¿¤³¤È¤Ë¤è¤ë¤È¸À¤ï¤ì¤Æ¤¤¤Þ¤¹¡£

¤¿¤Àñ¤Ë¤¿¤ë¤ß¤ò¼£ÎŤ¹¤ë¡¢¥·¥ï¤ÎÀþ¤ò¾Ã¤¹¡¢¥·¥ï¤À¤±¤òËä¤á¤ë¤Ê¤É¡¢ÉôʬŪ¤Ë¥±¥¢¤ò¤·¤Æ¤â¡¢Ê¿Ã³¤Êðú¤À¤Á¤Ë¤Ê¤Ã¤Æ¤·¤Þ¤¤¤Þ¤¹¤Î¤Ç¡¢´éÁ´ÂΤΥХé¥ó¥¹¤òÀ°¤¨¤Æ¡¢±ú¤ß¤ä¤¯¤Ü¤ß¤Î¥Ü¥ê¥å¡¼¥àÊä½¼¤Ê¤É¤ÎΩÂÎŪ¤Ê¼£ÎŤò¹Ô¤¦¤³¤È¤Ç¡¢¼«Á³¤Ê»Å¾å¤¬¤ê¤Ë¤Ê¤ê¤Þ¤¹¡£

²£´é¤âÈþ¤·¤¯¤Ê¤ë¤è¤¦¤Ë

²£´é¤âÈþ¤·¤¯¤Ê¤ë¤è¤¦¤Ë

²£¤«¤é¸«¤Æ¤âÈþ¤·¤¯¤Ê¤ë¤è¤¦¤Ë¡¢¥Ü¥ê¥Õ¥È XC¤òÃíÆþ¤·¤Þ¤¹¡£

É¡¡¢³Ü¡¢¸ý¸µ¤Î¥Ð¥é¥ó¥¹¤ò¹Í¤¨¤Æ¡¢¤É¤ÎÊý¸þ¤«¤é¸«¤Æ¤âÈþ¤·¤µ¤¬°ú¤­Î©¤Ä¤è¤¦¤Ë»Ü½Ñ¤·¤Þ¤¹¡£

ÃíÆþÁ°¤Î¥Ç¥¶¥¤¥ó

¥Ò¥¢¥ë¥í¥ó»À¤ÎÃí¼Í¤Î¥Ç¥¶¥¤¥ó¤ò¤·¤Æ¤¤¤ë¤È¤³¤í

¤É¤ÎÉô°Ì¤Ë¤É¤Î¤¯¤é¤¤ÃíÆþ¤¹¤ì¤Ð¤è¤¤¤«¤ò¡¢ÃíÆþ¤¹¤ë°å»Õ¼«¿È¤¬Ä¾Àܥǥ¶¥¤¥ó¤·¤Þ¤¹¡£¤³¤Î¥Ç¥¶¥¤¥ó¤òÃúÇ«¤Ë¤·¤Ã¤«¤ê¹Ô¤¦¤«¤É¤¦¤«¤Ç»Å¾å¤¬¤ê¤ËÂ礭¤¯º¹¤¬¤Ä¤¯·¹¸þ¤¬¤¢¤ê¤Þ¤¹¡£

±ú¤ó¤Ç¤¤¤ë²Õ½ê¡¢¥Ü¥ê¥å¡¼¥à¤ò½Ð¤·¤¿¤¤¸Ä½ê¤Ê¤Éµ¤¤Ë¤Ê¤ë¸Ä½ê¤ò¤É¤¦ÊѤ¨¤¿¤¤¤«¡¢¼£ÎÅÁ°¤Ë°å»Õ¤Ë¤ªÅÁ¤¨¤¯¤À¤µ¤¤¡£´µ¼ÔÍͤΤ´Í×˾¤ò¤â¤È¤Ë¡¢¤ª¤Ç¤³¡¢Ìܤμþ¤ê¡¢¤Û¤¦¤ì¤¤Àþ¡¢³Ü¤Ê¤É¤Ë¥Ç¥¶¥¤¥ó¤·¤Æ¤¤¤­¤Þ¤¹¡£

¥Ç¡¼¥¿¤«¤é¸«¤ë¥Ü¥ê¥Õ¥È XC

¥Ò¥¢¥ë¥í¥ó»À¤Î¥Ç¡¼¥¿¤Î¥¤¥á¡¼¥¸

¥Ü¥ê¥Õ¥È XC¤Î¼Â¸³¥Ç¡¼¥¿¤ò¾Ò²ð¤·¤Þ¤¹¡£

¢¨°úÍѸµ¡§¥¢¥é¥¬¥ó¥¸¥ã¥Ñ¥ó¼Ò

¥Ü¥ê¥Õ¥È XC¤ÎÄãµÛ¿åÀ­¤Ë´Ø¤·¤Æ

¼Â¸³·ë²Ì

¥Ü¥ê¥Õ¥È XC¤Ë¿å¤ò´Þ¤Þ¤»¤¿¤È¤­¤Ë¤É¤ÎÄøÅÙ¡¢¿å¤òµÛ¼ý¤¹¤ë¤«¤Î¼Â¸³¤Ç¤¹¡£¥²¥ë¤¬¥Ü¥ê¥Õ¥È XC¤Ç¤¹¡£

¥Ü¥ê¥Õ¥È XC(¥²¥ë)¤È¥ê¥ó»À´Ë¾×±Õ(1¡§7)¤Îº®¹çʪ¤ò1»þ´Ö³ÉÙ¤·¡¢ºÇÂçµÛ¿åÎ̤Ë㤷¤¿»þÅÀ¤Ç¥²¥ë¤ÎËĽáÎ̤ò¬Äꤷ¤Þ¤·¤¿¡£3500rpm¤Ç10ʬ´Ö±ó¿´Ê¬Î¥¤·¡¢¥²¥ë¤ËµÛ¿å¤µ¤ì¤Æ¤¤¤Ê¤¤¿åÎ̤ò10¦ÌLÀÄ¿§À÷¿§±Õ¤ÇÀ÷¿§¤¹¤ë¤³¤È¤Ç²Ä»ë²½¤·¤Æ¤¤¤Þ¤¹¡£

¤³¤Î²èÁü¤Î¤è¤¦¤Ë¡¢¥Ü¥ê¥Õ¥È XC¤Ï¿å¤ò¤¢¤Þ¤êµÛ¼ý¤·¤Ê¤¤¤è¤¦¤Ë¤·¤Æ¤¤¤Þ¤¹¡£¿å¤ò¤¢¤Þ¤êµÛ¼ý¤·¤Ê¤¤¤Î¤Ç¡¢·Á¤¬Êø¤ì¤Ë¤¯¤¯¤Ê¤Ã¤Æ¤¤¤Þ¤¹¡£¤³¤Î¤è¤¦¤Ë»ý³´ü´Ö¤¬Ä¹¤¯¤Ê¤ë¤è¤¦¤Ëºî¤é¤ì¤Æ¤¤¤Þ¤¹¡£

  • 1. Bernardin A et al. Presented at Anti-Aging Medicine European Congress(AMEC) 2013
  • 2. Goodman G et al. Plast Reconstr Surg 2015; 136(5 Suppl): 139S-148S

¥Ü¥ê¥Õ¥È XC¤Î¥ê¥Õ¥ÈÎϤ˴ؤ·¤Æ

¥Ü¥ê¥Õ¥È XC¤Î¥ê¥Õ¥ÈÎÏ

¥Ü¥ê¥Õ¥È XC¤Î¥ê¥Õ¥ÈÎϤ˴ؤ·¤Æ¤Î¼Â¸³¤Ç¤¹¡£¥Ü¥ê¥Õ¥ÈXC¤Ï¡¢¥Ü¥ê¥å¡¼¥ÞXC¤è¤ê½À¤é¤«¤¤¤Î¤Ç¡¢¥ê¥Õ¥ÈÎϤÏÎô¤ê¤Þ¤¹¤¬¡¢¥¦¥ë¥È¥éXC¤è¤ê¹â¤¤¥ê¥Õ¥ÈÎϤˤʤäƤ¤¤Þ¤¹¡£

ÃíÆþľ¸å¡¢1.0mm¤«¤é0.8£í£í¤Þ¤Ç²¼¤¬¤ê¡¢¤½¤Î¸å¤Ï12½µ´Ö¸å¤Þ¤Ç¤Ç¡¢0.6£í£íÄøÅ٤ޤǤ·¤«¸º¤Ã¤Æ¤¤¤Þ¤»¤ó¡£

N¡á10

  • 1. Bernardin A et al. Poster presentation at AMEC EMAA 2013¡¢
  • 2. Hee CK et al. Dermatol Surg 2015; 41 Suppl 1: S373-S381

¥Ü¥ê¥Õ¥È XC¤Î¿ÆÏÂÀ­¤Ë´Ø¤·¤Æ

¥Ü¥ê¥Õ¥È XC¤Î¿ÆÏÂÀ­

¥Ü¥ê¥Õ¥È XC¤Î¿ÆÏÂÀ­¤òÄ´¤Ù¤ë¼Â¸³¤Ç¤¹¡£

¤³¤Î²èÁü¤ÎÀÖ¤¤¿§¤ÎÉôʬ¤¬¡¢¥³¥é¡¼¥²¥óÁÈ¿¥¤Ç¡¢ÀĤ¤¿§¤ÎÉôʬ¤¬¥Ü¥ê¥Õ¥È XC¤Ë¤Ê¤ê¤Þ¤¹¡£
¿§ÉÕ¤±¤Ï¡¢Van GiesonÀ÷¿§¤Ç¤¹¡£
¤³¤Î¼Â¸³¤¬ÀäÂФǤϤ¢¤ê¤Þ¤»¤ó¤¬¡¢¥³¥é¡¼¥²¥óÁÈ¿¥¤È¥Ü¥ê¥Õ¥ÈXC¤¬¤Ê¤¸¤ó¤Ç¤¤¤ë¤è¤¦¤Ë¸«¤é¤ì¤Þ¤¹¡£¤³¤ÎÆëÀ÷¤ß¤ò¡¢¡Ö¿ÆÏÂÀ­¡×¤È¤¤¤¦¸ÀÍÕ¤Çɽ¸½¤·¤Æ¤¤¤Þ¤¹¡£

¥Ü¥ê¥Õ¥È XC¤¬ÁÈ¿¥¤ÈÈéÉæɽÌ̤˶ᤤÀõ¤¤ÁؤǤʤ¸¤à¤Î¤Ç¡¢ÈéÉæɽÌ̤˥ҥ¢¥ë¥í¥ó»À¤¬Â¿¤¯¤Ê¤ê¡¢¸Ä¿Íº¹¤Ï¤¢¤ê¤Þ¤¹¤¬¡¢½á¤Ã¤¿È©¤Î°õ¾Ý¤òÍ¿¤¨¤ë¤³¤È¤¬¤Ç¤­¤Þ¤¹¡£

´é¤Î¥·¥ï(¤Û¤¦¤ì¤¤Àþ¡¢³Û¡¢ÌÜ¿¬¤Ê¤É)¤ËÃíÆþ¤·¤¿¥Ò¥¢¥ë¥í¥ó»À¤Î½¤Àµ

¥Ò¥¢¥ë¥í¥Ë¥À¡¼¥¼¤Î¥Ñ¥Ã¥±¡¼¥¸³°´Ñ

¥Ò¥¢¥ë¥í¥ó»À¤ò´é¤Î¥·¥ï(¤Û¤¦¤ì¤¤Àþ¡¢³Û¡¢ÌÜ¿¬¤Ê¤É)¤ËÃíÆþ¸å¡¢¥Ò¥¢¥ë¥í¥Ë¥À¡¼¥¼¤È¤¤¤¦¥Ò¥¢¥ë¥í¥ó»À¤Î¹ÚÁǤòÃíÆþ¤¹¤ë»ö¤Ç¡¢¥Ò¥¢¥ë¥í¥ó»À¤òÍϤ«¤¹¤³¤È¤¬¤Ç¤­¤Þ¤¹¡£

¥Ò¥¢¥ë¥í¥Ë¥À¡¼¥¼¤Ï¡¢ÃíÆþ¤·¤¿¥Ò¥¢¥ë¥í¥ó»À¤ÎÎ̤ò¸º¤é¤·¤¿¤ê¡¢ÃíÆþ¸å¤ÎÉÔ¼«Á³¤µ¤ò½¤Àµ¤·¤¿¤¤¾ì¹ç¤Ë»ÈÍѤµ¤ì¤Þ¤¹¡£

¥¢¥é¥¬¥ó¥Ó¥å¡¼¥Æ¥£¡¼¥¢¥ï¡¼¥É¤ò4ǯϢ³¤Ç¼õ¾Þ

¥Ó¥å¡¼¥Æ¥£¡¼¥¢¥ï¡¼¥É¤Îɽ¾´¾õ

2020ǯ¤ÎÀܵҥµ¡¼¥Ó¥¹¤ò¤´É¾²Á¤¤¤¿¤À¤­¡¢¥¢¥é¥¬¥ó¥¸¥ã¥Ñ¥ó¼Ò¤è¤ê¡¢¥¢¥é¥¬¥ó¥Ó¥å¡¼¥Æ¥£¡¼¥¢¥ï¡¼¥É2020¤ò¤¤¤¿¤À¤­¤Þ¤·¤¿¡£

º£Ç¯¤Ç£´Ç¯Ï¢Â³¤Ë¤Ê¤ê¤Þ¤¹¡£

º£¸å¤â¶¦Î©ÈþÍÆ¥°¥ë¡¼¥×°ì´Ý¤È¤Ê¤Ã¤Æ¡¢ÈþÍÆ°åÎŤÎȯŸ¤Ë¿ÔÎϤ·¤Æ¤Þ¤¤¤ê¤Þ¤¹¡£

¥¸¥å¥Ó¥À¡¼¥à¥Ó¥¹¥¿® ¥Ü¥ê¥Õ¥È XC¤Î³µÍ×

¼ê½ÑÎÁ¶â ¢¡¥Ü¥ê¥Õ¥È XC
1cc¡§¥79,800¡ÊÀǹþ¡Ë
2cc¡§¥135,660¡ÊÀǹþ¡Ë
3cc¡§¥191,520¡ÊÀǹþ¡Ë
4cc¡§¥239,400¡ÊÀǹþ¡Ë
¼ê½Ñ»þ´Ö Ìó30ʬÄøÅÙ
¥À¥¦¥ó¥¿¥¤¥à ¤Û¤Ü¤Ê¤·
Ä̱¡²ó¿ô ÆäËɬÍפʤ·
¥«¥¦¥ó¥»¥ê¥ó¥°ÅöÆü¤Î¼£ÎÅ ²Ä
Æþ±¡¤ÎɬÍ×À­ ¤Ê¤·
À©¸Â»ö¹à Æäˤʤ·
»Å»ö¡¦³°½Ð ²Ä
¤½¤Î¾Æõ­»ö¹à ¤Ê¤·
  • ɽ¼¨ÎÁ¶â¤ÏÌܰ¤ζâ³Û¤È¤Ê¤ê¤Þ¤¹¡£
  • ½Ñ¸å¤Î¥¢¥Õ¥¿¡¼¥Õ¥©¥í¡¼¤â¤·¤Ã¤«¤ê¤·¤Æ¤ª¤ê¤Þ¤¹¡£ÄɲÃÎÁ¶â¤Ï°ìÀÚ¤«¤«¤ê¤Þ¤»¤ó¡£
    ¤¤¤Ä¤Ç¤â¤´±óθ¤Ê¤¯¡¢Ã´Åö°å¤Ë¤´ÁêÃ̤¯¤À¤µ¤¤¡£

¤·¤ï¡¦¤¿¤ë¤ß´ØÏ¢¥³¥é¥à

¤·¤ï¼£ÎŤο͵¤¼£ÎÅ

¤ªÈ©¤Î¥á¥Ë¥å¡¼

¶¦Î©ÈþÍƳ°²Ê¤Ç¼õ¤±¤é¤ì¤ë¤·¤ï¼£ÎÅ

¤³¤Î¥Ú¡¼¥¸¤Î´Æ½¤°å»Õ

  • CEO·óÁí³ç±¡Ä¹ µ×¼¡ÊÆ ½©¿Í(¤¯¤¸¤á ¤¢¤­¤Ò¤È)

    CEO·óÁí³ç±¡Ä¹

    µ×¼¡ÊÆ ½©¿Í(¤¯¤¸¤á ¤¢¤­¤Ò¤È)

    ÆüËÜÈþÍƳ°²Ê°å»Õ²ñÍý»ö
    ÆüËÜÈþÍƳ°²Ê³Ø²ñǧÄêÀìÌç°å

    • άÎò

      • 1983ǯ
        ¶âÂô°å²ÊÂç³Ø°å³ØÉô ´¶È
        1983ǯ
        ¹âÃΰå²ÊÂçÀ°·Á³°²ÊÆþ¶É
        1989ǯ
        ÅìµþËܱ¡(ÉÊÀî)³«±¡
        2002ǯ
        Ëܱ¡¤ò¿·½É¤Ë°Üž
        2013ǯ
        ¶äºÂ±¡±¡Ä¹½¢Ç¤
        2018ǯ
        Âè107²óÆüËÜÈþÍƳ°²Ê³Ø²ñ ³Ø²ñĹ½¢Ç¤
    • ¼ç¤Ê²ÃÌÁÃÄÂÎ

      ÆüËÜÈþÍƳ°²Ê°å»Õ²ñÍý»ö
      ÆüËÜ·ÁÀ®³°²Ê³Ø²ñ²ñ°÷
      ÆüËÜÈþÍƳ°²Ê³Ø²ñ²ñ°÷
      ÆüËÜÈþÍƳ°²Ê³Ø²ñǧÄêÀìÌç°å
      ÆüËÜæÌӳزñ²ñ°÷
      ËÌÊÆ»éËõ۰ú·ÁÀ®³°²Ê³Ø²ñ²ñ°÷
      ÆüËܹ£²ÃÎðÈþÍÆ°åÎųزñ²ñ°÷

¶¦Î©ÈþÍƳ°²Ê

¶¦Î©ÈþÍƳ°²Ê¡Ã¹Â¡¢¤·¤ï¼£ÎŤΥ¸¥å¥Ó¥À¡¼¥à¥Ó¥¹¥¿® ¥Ü¥ê¥Õ¥È XC¤Î¥Ú¡¼¥¸¤ò¤´Í÷¤Î³§ÍͤØ

¤³¤Î¥Ú¡¼¥¸¤Ï2024ǯ3·î¤ËºÇ½ª³Îǧ¤ò¤·¤Æ¤¤¤Þ¤¹¡£
¤³¤Î¥Ú¡¼¥¸¤Ç¤Ï¡¢¹Â¡¢¤·¤ï¼£ÎŤΥ¸¥å¥Ó¥À¡¼¥à¥Ó¥¹¥¿® ¥Ü¥ê¥Õ¥È XC¤Ë¤Ä¤¤¤Æ¤´³Îǧ失¤Þ¤¹¡£¥Ü¥ê¥Õ¥ÈXC¤ÎÃíÆþ¤Î»ÅÊý¤ä¡¢ÎÁ¶â¤Ê¤É¤ò²òÀ⤷¤Æ¤¤¤Þ¤¹¡£¶¦Î©ÈþÍƳ°²Ê¤Î¥Ò¥¢¥ë¥í¥ó»À¤ò»ÈÍѤ·¤¿¥·¥ï¡¢¹Â¼£ÎŤϡ¢É½¾ð¥¸¥ï¤ò¤Ï¤¸¤áÀõ¤¤¥·¥ï¡¢¿¼¤¤¥·¥ï¤Ê¤É¤µ¤Þ¤¶¤Þ¤Ê¥·¥ï¤ò¼£ÎŤǤ­¤Þ¤¹¡£¥·¥ï¤ä¹Â¤Ï¤ª°ì¿Í¤ª°ì¿Í°ã¤¤¤Þ¤¹¤·¡¢Ç¯Âå¤Ë¤è¤Ã¤ÆÌÜΩ¤Ä°ÌÃÖ¤âÊѤï¤ë¤¿¤á¡¢°å»Õ¤¬´µ¼ÔÍͤÈÃúÇ«¤Ë¥«¥¦¥ó¥»¥ê¥ó¥°¤ò¹Ô¤¤¡¢¤ª°ì¿Í¤ª°ì¿Í¤Î¾õÂ֤˹ç¤ï¤»¤Æ¥Ò¥¢¥ë¥í¥ó»À¤òÃíÆþ¤·¡¢¥·¥ï¤ä¹Â¤ò¼£ÎŤ·¤Þ¤¹¡£¥¸¥å¥Ó¥À¡¼¥à¥Ó¥¹¥¿® ¥Ü¥ê¥Õ¥È XC¤Ï¥Ò¥¢¥ë¥í¥ó»À¤Ë¤Ê¤ê¤Þ¤¹¤Î¤Ç¡¢ÃíÆþ¸å½¤Àµ¤·¤¿¤¤¾ì¹ç¤â¥Ò¥¢¥ë¥í¥Ë¥À¡¼¥¼¤òÃíÆþ¤¹¤ë¤³¤È¤Ç¡¢¥Ò¥¢¥ë¥í¥ó»À¤òÍϤ«¤·½¤Àµ¤¹¤ë¤³¤È¤¬¤Ç¤­¤Þ¤¹¡£¶¦Î©ÈþÍƳ°²Ê¤Ï¥¸¥å¥Ó¥À¡¼¥à¥Ó¥¹¥¿® ¥Ü¥ê¥Õ¥È XC¤òÀ½Â¤ÈÎÇä²ñ¼Ò¤Î¥¢¥é¥¬¥ó¡¦¥¸¥ã¥Ñ¥ó³ô¼°²ñ¼Ò¤è¤êÉʼÁ´ÉÍý¤òÅ°Ä줵¤ì¤¿¾õÂÖ¤ÇǼÉʤ·¤Æ¤¤¤Þ¤¹¡£

')